News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
733,312 Results
Type
Article (43808)
Company Profile (303)
Press Release (689190)
Multimedia
Podcasts (98)
Webinars (17)
Section
Business (206625)
Career Advice (2130)
Deals (36992)
Drug Delivery (118)
Drug Development (82107)
Employer Resources (174)
FDA (16615)
Job Trends (15217)
News (351023)
Policy (33364)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2641)
Accelerated approval (34)
Adcomms (26)
Allergies (146)
Alliances (50262)
ALS (172)
Alzheimer's disease (1692)
Antibody-drug conjugate (ADC) (325)
Approvals (16876)
Artificial intelligence (569)
Autoimmune disease (165)
Automation (42)
Bankruptcy (371)
Best Places to Work (11792)
BIOSECURE Act (20)
Biosimilars (195)
Biotechnology (199)
Bladder cancer (162)
Brain cancer (61)
Breast cancer (651)
Cancer (4931)
Cardiovascular disease (419)
Career advice (1800)
Career pathing (38)
CAR-T (297)
CDC (49)
Celiac Disease (2)
Cell therapy (783)
Cervical cancer (36)
Clinical research (70134)
Collaboration (1762)
Company closure (4)
Compensation (1173)
Complete response letters (61)
COVID-19 (2754)
CRISPR (96)
C-suite (870)
Cystic fibrosis (146)
Data (6326)
Decentralized trials (2)
Denatured (25)
Depression (141)
Diabetes (510)
Diagnostics (6777)
Digital health (52)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (284)
Drug pricing (191)
Drug shortages (29)
Duchenne muscular dystrophy (235)
Earnings (90586)
Editorial (59)
Employer branding (21)
Employer resources (154)
Events (118201)
Executive appointments (991)
FDA (19798)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1506)
Gene editing (204)
Generative AI (51)
Gene therapy (617)
GLP-1 (1005)
Government (4757)
Grass and pollen (6)
Guidances (384)
Healthcare (19119)
HIV (64)
Huntington's disease (45)
IgA nephropathy (86)
Immunology and inflammation (264)
Immuno-oncology (63)
Indications (118)
Infectious disease (3034)
Inflammatory bowel disease (199)
Inflation Reduction Act (14)
Influenza (121)
Intellectual property (256)
Interviews (340)
IPO (16752)
IRA (53)
Job creations (3769)
Job search strategy (1499)
JPM (61)
Kidney cancer (17)
Labor market (86)
Layoffs (580)
Leadership (34)
Legal (8165)
Liver cancer (92)
Longevity (15)
Lung cancer (669)
Lymphoma (385)
Machine learning (42)
Management (61)
Manufacturing (833)
MASH (168)
Medical device (13962)
Medtech (14019)
Mergers & acquisitions (21334)
Metabolic disorders (1303)
Multiple sclerosis (166)
NASH (17)
Neurodegenerative disease (328)
Neuropsychiatric disorders (95)
Neuroscience (2968)
Neurotech (1)
NextGen: Class of 2026 (6673)
Non-profit (4570)
Now hiring (68)
Obesity (616)
Opinion (282)
Ovarian cancer (168)
Pain (199)
Pancreatic cancer (232)
Parkinson's disease (288)
Partnered (33)
Patents (512)
Patient recruitment (501)
Peanut (58)
People (59498)
Pharmaceutical (71)
Pharmacy benefit managers (30)
Phase 1 (21858)
Phase 2 (30833)
Phase 3 (23024)
Pipeline (5474)
Policy (296)
Postmarket research (2599)
Preclinical (9287)
Press Release (66)
Prostate cancer (243)
Psychedelics (50)
Radiopharmaceuticals (291)
Rare diseases (868)
Real estate (6054)
Recruiting (70)
Regulatory (24951)
Reports (54)
Research institute (2447)
Resumes & cover letters (366)
Rett syndrome (27)
RNA editing (17)
RSV (82)
Schizophrenia (154)
Series A (249)
Series B (196)
Service/supplier (12)
Sickle cell disease (98)
Special edition (24)
Spinal muscular atrophy (159)
Sponsored (42)
Startups (3718)
State (2)
Stomach cancer (18)
Supply chain (107)
Tariffs (85)
The Weekly (71)
Vaccines (1035)
Venture capital (91)
Weight loss (399)
Women's health (93)
Worklife (18)
Date
Last 7 days (571)
Last 30 days (2285)
Last 365 days (30385)
2026 (4048)
2025 (30961)
2024 (35770)
2023 (40358)
2022 (51486)
2021 (56079)
2020 (54531)
2019 (47159)
2018 (35568)
2017 (32656)
2016 (32095)
2015 (38109)
2014 (31853)
2013 (26903)
2012 (29101)
2011 (29786)
2010 (27897)
Location
Africa (774)
Alabama (84)
Alaska (7)
Arizona (313)
Arkansas (13)
Asia (40322)
Australia (6581)
California (11448)
Canada (3330)
China (1126)
Colorado (481)
Connecticut (487)
Delaware (341)
Europe (87206)
Florida (1716)
Georgia (363)
Hawaii (3)
Idaho (64)
Illinois (879)
India (69)
Indiana (531)
Iowa (22)
Japan (438)
Kansas (128)
Kentucky (41)
Louisiana (27)
Maine (72)
Maryland (1404)
Massachusetts (8236)
Michigan (331)
Minnesota (632)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (124)
New Hampshire (82)
New Jersey (3060)
New Mexico (29)
New York (3028)
North Carolina (1474)
North Dakota (8)
Northern California (5593)
Ohio (342)
Oklahoma (21)
Oregon (42)
Pennsylvania (2310)
Puerto Rico (24)
Rhode Island (48)
South America (1153)
South Carolina (67)
South Dakota (1)
Southern California (4455)
Tennessee (179)
Texas (1764)
United States (40670)
Utah (346)
Vermont (1)
Virginia (266)
Washington D.C. (83)
Washington State (932)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
733,312 Results for "myokardia inc acquired by bms".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
FDA Action Alert: BMS, GSK, Amgen and More
The FDA’s docket in December includes decisions for two big biologic franchises: BMS’s Breyanzi and Amgen’s Uplizna.
December 1, 2025
·
5 min read
·
Tristan Manalac
Cancer
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments
The partnership will allow BMS to advance a T cell–based therapy that is only activated once in the vicinity of a tumor.
January 22, 2026
·
2 min read
·
Tristan Manalac
China
BMS Forges $1B+ Antibody Alliance With Chinese Firm Harbour
BMS is Harbour’s second powerhouse partner this year after the Chinese biotech signed a potential $4.68 billion deal with AstraZeneca in March.
December 17, 2025
·
1 min read
·
Tristan Manalac
Approvals
Cytokinetics Wins FDA Approval, Clearing Way to Challenge BMS in Heart Disease Market
Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos.
December 22, 2025
·
2 min read
·
Nick Paul Taylor
Series A
MyoKardia Alumni Launch Kardigan with $300M to Tackle Heart Disease
After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are back together with a mission to make cardiovascular disease curable and preventable.
January 10, 2025
·
2 min read
·
Heather McKenzie
Alzheimer’s disease
BMS Delays Cobenfy Alzheimer’s Psychosis Data After ‘Irregularities’ in Phase III Study
Analysts had noted “unease” from investors regarding the state of the Phase III ADEPT-2 trial, with BMS at one point telling Leerink Partners that the reopening of enrollment would be a “significant development.”
December 3, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
BMS-Partnered Cellares Raises $257M for Cell Therapy Manufacturing Expansion
Cellares, which last year became the first company to receive the FDA’s new advanced manufacturing technology designation, expects to support clinical production this year and offer commercial-scale manufacturing services in 2027.
January 28, 2026
·
2 min read
·
Nick Paul Taylor
Cardiovascular disease
Cytokinetics’ Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy?
After 27 years in business, Cytokinetics hopes to pit its own cardiac myosin inhibitor against one it initially developed—now owned by Bristol Myers Squibb—in a market worth billions. Aficamten has a PDUFA date of Dec. 26.
December 19, 2025
·
5 min read
·
Dan Samorodnitsky
Earnings
BMS Beats Again Despite Eliquis and Cobenfy Disappointments
Bristol Myers Squibb delivered better than expected fourth quarter earnings, but Eliquis missed expectations while Cobenfy continues to struggle with uptake.
February 5, 2026
·
2 min read
·
Dan Samorodnitsky
Startups
BMS, Bain Birth Biotech for Autoimmune Disorders
BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus erythematosus and plaque psoriasis, and $300 million in funds from Bain Capital.
July 29, 2025
·
2 min read
·
Tristan Manalac
1 of 73,332
Next
